Testosterone deficiency (TD) therapy if prostate cancer

Testosterone therapy and prostate cancer

Testosterone therapy can be offered to men with symptomatic TD and treated localised low-risk prostate cancer (Gleason score <8, stages 1-2, preoperative prostate specific antigen (PSA) <10ng/mL), as long as it is not started before 1 year of follow-up and they have no evidence of active disease (based on measured PSA level, DRE result and absence of metastases).

Reference:

1. Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.